Biomarkers and Real-World Practice: Where Do They Fit with Alzheimer’s Disease?

This activity is part of a series


Anna D. Burke, MD
Karsten Solheim Chair for Dementia
Director of Alzheimer’s and Memory Disorders Division
Director of Neuropsychiatry
Department of Neurology
Barrow Neurological Institute
Phoenix, AZ
Anna D. Burke, MD

Anna D. Burke, MD, is a board-certified geriatric psychiatrist, the Karsten Solheim Chair for Dementia, and the Director of the Alzheimer’s and Memory Disorders Division at Barrow Neurological Institute in Phoenix, Arizona. She also currently directs the Department of Neuropsychiatry at Barrow Neurological Institute. Barrow Neurological Institute is a world-class neurological and neurosurgical institute with a mission to accept challenges, reject norms, and push boundaries. The Barrow Alzheimer’s and Memory Disorders Division is one of the leading clinical and research institutes in the world, championing research in neurodegenerative disorders.

Dr. Burke has worked extensively with patients and families suffering with neurodegenerative disorders including Alzheimer’s disease (AD). Her area of expertise includes the diagnosis and management of cognitive disorders and the treatment of challenging behavioral and psychiatric disturbances that result from neurological conditions. In addition to her clinical work, she has led the development of comprehensive multispecialty clinical care models focused on improving the quality of care for individuals with cognitive impairment as well as improving the diagnosis and management of AD and related dementias in the community. Dr. Burke is a well-respected researcher, having led over 100 clinical trials of investigational therapies for AD and related dementias, and is a well-respected author and key opinion leader in the field.

Michelle M. Mielke, PhD
Chair, Department of Epidemiology and Prevention
Professor of Epidemiology and Prevention
Professor of Gerontology and Geriatric Medicine
Division of Public Health Sciences
Wake Forest University School of Medicine
Winston-Salem, NC
Michelle M. Mielke, PhD

Michelle M. Mielke, PhD, is Chair of the Department of Epidemiology and Prevention, Professor of Epidemiology, and Professor of Gerontology and Geriatric Medicine at Wake Forest University School of Medicine. She works as a translational epidemiologist to further understand the etiology and epidemiology of neurodegenerative diseases. One focus of her research is understanding the utility of blood-based biomarkers for implementation at the population level for screening and diagnosing Alzheimer’s disease and related dementias. Another focus of Dr. Mielke’s research is on understanding sex and gender differences in the development and progression of Alzheimer’s disease and related dementias. She is principal investigator of several National Institutes of Health (NIH)-funded clinical and epidemiological-based grants and has published over 400 manuscripts. Dr. Mielke received the John R. Raymond Mentor Award from the Women Scholars Initiative and recently became a Fellow in the American Association for the Advancement of Science (AAAS), Section on Neuroscience.

Statement of Need

Rapidly advancing biomarker research is adding much-needed clarity to the differential diagnosis of Alzheimer’s disease (AD), particularly in early disease, but there are delays in the detection and diagnosis of AD. To combat these delays and allow patients access to early interventions that may slow disease progression, it is imperative that health care professionals involved in AD/dementia care are aware of advances in AD diagnostics and are able to translate these advances in the real-world practice setting.

In this CME Outfitters Snack, expert faculty will discuss biomarker research findings presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference, review the identification and measurement of AD pathophysiology, examine a framework for evidencing biomarker profiles of AD, provide updates on prognostic performance and interpretation of biomarkers, and conduct a case-based discussion of clinical impacts and applications.

Learning Objective

Interpret biomarker-based investigations to identify patients with AD pathology in clinical and research settings.

Financial Support

This activity is supported by an educational grant from Lilly.

Target Audience

Dementia specialists, neurologists, psychiatrists, neurology and psychiatry nurse practitioners (NPs) and physician associates (PAs), and other clinicians caring for patients with AD in the United States and globally (with the exception of UK-based clinicians)

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Interprofessional (IPCE) 0.5

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME) 0.5

CME Outfitters, LLC, designates this Enduring Material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 0.5

This activity is designated for 0.50 contact hours.

PAs (AAPA) 0.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until 11/30/2024. PAs should only claim credit commensurate with the extent of their participation.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

Dr. Burke reports the following financial relationships:

Advisory Board and Consultant: Eisai Inc.; Lilly; and Roche

Dr. Mielke reports the following financial relationships:

Advisory Board: Biogen; Eisai Inc.; Lilly; Merck & Co., Inc.; Roche; and Siemens Healthineers

Speakers Bureau: Roche

Disclosures were obtained from the following peer reviewer and CME Outfitters, LLC, staff, with no disclosures to report:

  • Marlon (Tony) Graham, MD (peer reviewer)
  • Sonya Lewis, PhD (peer reviewer)
  • Susan Perry (planning committee)
  • Kellie Busby, PharmD, BCPP (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).


Biomarkers and Real-World Practice: Where Do They Fit with Alzheimer’s Disease?
Event Date: 11/30/2023